Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

INTRODUCTION. A KRAS mutation represented the first genomic biomarker to predict lack of benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy in advanced colorectal cancer (CRC). Expanded RAS testing has further refined the treatment approach, but understanding of genomic alter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Rankin, Andrew, Klempner, Samuel J., Erlich, Rachel, Sun, James X., Grothey, Axel, Fakih, Marwan, George, Thomas J., Lee, Jeeyun, Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2016
Assuntos:
Cancer Diagnostics and Molecular Pathology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5189622/
https://ncbi.nlm.nih.gov/pubmed/27682134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0148
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados